[Rational hypoglycemic therapy - nephro-diabetologic view]
Marcin Kosmalski1, Ilona Kurnatowska1
1Zakład Farmakologii Klinicznej, I Katedra Chorób Wewnętrznych Uniwersytetu Medycznego w Łodzi, Oddział Nefrologii, Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego w Łodzi.
Abstract:
Diabetes is a heterogenous group of diseases with chronic hyperglycemia, which is associated with the risk of many complications, including diabetic kidney disease. Micro- and macroangiopathy in hyperglycemic environment leads to organ failure, including end-stage renal disease, requiring dialysis or kidney transplantation. However, diabetes is not the only cause leading to kidney dysfunction in this patient population. A patient with diabetes should be monitored regularly for proteinuria and glomerular filtration rate and depending on advancement of kidney disease or suspicion other than diabetes cause of kidney damage, should also be covered by nephrological care. Appropriately selected hypoglycemic drugs and their doses, in combination with appropriate non-pharmacological treatment, in the patients with different stages of kidney disease, not only reduces the risk of drug-induced side effects but, above all, may slow the progression of kidney damage and reduce the risk of other complications in this group of patients. Recently, there have been many new groups of hypoglycemic agents that can be used in the treatment of patients with kidney disease. The aim of this study is to present the current possibilities of hypoglycemic therapy in patients with different stages of chronic kidney disease. In addition, the relationship between individual groups of hypoglycemic agents and the renal benefits and risk was analyzed.
Insights
Managing diabetes and chronic kidney disease requires careful selection of hypoglycemic drugs. This study analyzes new agents, their renal benefits, and risks across different kidney disease stages.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus causes chronic hyperglycemia, increasing risks of complications like diabetic kidney disease.
- Hyperglycemia-induced micro- and macroangiopathy can lead to end-stage renal disease, necessitating dialysis or transplantation.
- Kidney dysfunction in diabetic patients may stem from causes other than diabetes, requiring nephrological monitoring.
Purpose of the Study:
- To review current hypoglycemic therapy options for patients with varying stages of chronic kidney disease.
- To analyze the renal benefits and risks associated with different classes of hypoglycemic agents.
Main Methods:
- Literature review of current hypoglycemic agents and their use in chronic kidney disease.
- Analysis of studies examining the impact of specific hypoglycemic drug classes on renal function and outcomes.
Main Results:
- Newer hypoglycemic agents offer potential therapeutic benefits for diabetic patients with chronic kidney disease.
- Careful drug selection and dosage adjustment are crucial to minimize adverse effects and optimize renal protection.
- Individualized treatment strategies considering kidney function are essential for managing hyperglycemia and slowing disease progression.
Conclusions:
- Hypoglycemic therapy in diabetic patients with chronic kidney disease requires individualized approaches.
- Understanding the renal effects of different hypoglycemic agents is key to improving patient outcomes.
- Ongoing research into novel agents and treatment paradigms is vital for managing this complex patient population.
Related Concept Videos
Rational Emotive Behavior Therapy
Rationalizing Substitutions
Rational Expressions
Oral Hypoglycemic Agents: Glinides
Asymptotes in Rational Functions
Oral Hypoglycemic Agents: Sulfonylureas


